<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03776825</url>
  </required_header>
  <id_info>
    <org_study_id>2134</org_study_id>
    <nct_id>NCT03776825</nct_id>
  </id_info>
  <brief_title>Permacol Paste in Perianal Crohn's Disease</brief_title>
  <acronym>UPpCro</acronym>
  <official_title>Use of Permacol Paste in Perianal Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect data about the efficacy of Permacol Paste treatment
      in perianal Crohn's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational prospective cohort study aimed to assess the efficacy of Permacol
      Paste treatment in perianal Crohn's Disease, by evaluating the healing rate and quality of
      life of 20 patients prospectively indicated to Permacol Paste treatment during one year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perianal fistula closure rate</measure>
    <time_frame>12 months</time_frame>
    <description>Complete fistula closure will be defined as absence of spontaneous suppuration or suppuration on applying gentle pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life will be assessed using the Inflammatory Bowel Disease Quality of Life (IBDQ). IBDQ is a disease-specific questionnaire included 32 questions. The questions consisted of 4 domains as follows: Bowel symptoms (10 questions), systemic symptoms (5 questions), emotional functioning (12 questions), and social functioning (5 questions). Every question score ranged from 1 to 7 which 7 corresponded to the highest level of functioning. Total score ranged from 32 to 224. Higher score showed higher quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients continence</measure>
    <time_frame>12 months</time_frame>
    <description>Continence will be assessed by means of the Cleveland Clinic Incontinence Score (CCIS, or Wexner scale). This scoring system cross-tabulates frequencies and different anal incontinence presentations (Gas/Liquid/Solid/Pad use/Need for lifestyle alterations) and sums the returned score to a total of 0-20 (where 0 = perfect continence and 20 = complete incontinence).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Perianal Fistula</condition>
  <arm_group>
    <arm_group_label>Perianal Crohn's Disease</arm_group_label>
    <description>Permacol Paste injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Permacol Paste</intervention_name>
    <description>Permacol Paste Injection</description>
    <arm_group_label>Perianal Crohn's Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Perianal Crohn's Disease Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18, any sex

          -  Diagnosis of CD at least 6 months earlier in accordance with clinical, endoscopic,
             histological an/or radiological criteria

          -  Presence of perianal fistulas with maximum 3 external openings and a maximum of 2
             internal openings, assessed by physical examination and MRI

          -  Non-active or mildly active luminal CD defined by a CDAI &lt; 220

        Exclusion Criteria:

          -  CDAI &gt; 220

          -  Dominant luminal active CD requiring immediate surgical or medical therapy

          -  Fistula with &gt; 3 external openings and &gt; 2 internal openings

          -  Severe active proctitis and/or rectal stenosis

          -  Abscess or pelvic collection &gt; 2 cm diameter

          -  Concomitant rectovaginal fistulas

          -  Concomitant steroid treatment or treated with steroids in the last 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Antonino Spinelli, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesca Di Candido, MD</last_name>
    <phone>+390282247776</phone>
    <email>francesca.di_candido@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annalisa Maroli, PhD</last_name>
    <phone>+390282247776</phone>
    <email>annalisa.maroli@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Di Candido, MD</last_name>
      <phone>0282247776</phone>
      <email>francesca.di_candido@humanitas.it</email>
    </contact>
    <contact_backup>
      <last_name>Annalisa Maroli, PhD</last_name>
      <phone>+390282247776</phone>
      <email>annalisa.maroli@humanitas.it</email>
    </contact_backup>
    <investigator>
      <last_name>Antonino Spinelli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>December 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2018</study_first_posted>
  <last_update_submitted>February 18, 2019</last_update_submitted>
  <last_update_submitted_qc>February 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

